Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

Publication | Closed Access

DOI

191

Citations

References

2015

Year

Yohann Loriot, Kurt Miller, Cora N. Sternberg, Karim Fizazi, Johann S. de Bono, Simon Chowdhury, Celestia S. Higano, Sarah B. Noonberg, Stefan Holmström, Harry H. Mansbach,

The Lancet Oncology

UrologyHealth-related QualityPain MedicineMedicineSkeletal-related EventsCancer ManagementClinical TrialsCancer PainPharmacotherapyPain ManagementCancer TreatmentProstatic DiseaseOncologyChemotherapy-naive PatientsHealth Sciences